Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis-Reference-Cited by-同舟云学术

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

Published:2016-10-18 Issue:1 Volume:9 Page:
ISSN:1756-0500
Container-title:BMC Research Notes
language:en
Short-container-title:BMC Res Notes

Author:

Yamada Yoko,Matsubara Nobuaki,Tabata Ken-ichi,Satoh Takefumi,Kamiya Naoto,Suzuki Hiroyoshi,Kawahara Takashi,Uemura Hiroji,Yano Akihiro,Kawakami Satoru

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13104-016-2279-9.pdf

Reference24 articles.

1. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014;65(2):289–99.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

3. Katanoda K, Kamo K, Saika K, Matsuda T, Shibata A, Matsuda A, Nishino Y, Hattori M, Soda M, Ioka A, et al. Short-term projection of cancer incidence in Japan using an age-period interaction model with spline smoothing. Jpn J Clin Oncol. 2014;44(1):36–41.

4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.

5. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013;190(2):429–38.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis;Critical Reviews in Oncology/Hematology;2024-04

2. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?;European Urology Focus;2021-07

3. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer;PLOS ONE;2020-09-30

4. YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients;Pharmacogenomics;2020-08

5. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1;The Journal of Steroid Biochemistry and Molecular Biology;2019-09